Summit Therapeutics-Spon ADRSMMT
13F holders, Q2 2024 (June 30)2holders
1new positions
1sold out
$7.80avg. 13F price*
At the end of Q2 2024, 2 institutions reported holding Summit Therapeutics-Spon ADR (SMMT) in their 13F filings, unchanged from Q1 2024. 1 opened new positions and 1 sold out. The largest holders were Lindbrook Capital, LLC ($6K) and Rothschild Investment LLC ($429).
- Company
- Summit Therapeutics-Spon ADR
- CUSIP
- 86627R102
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $429 |
| Exits | 1 | $86 |
All 13F filers, Q1 2024 → Q2 2024: 339 shares bought and 21 shares sold, net +318 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Lindbrook Capital, LLC | 0.00% | Add +53.9% | 811 | $6K |
| Rothschild Investment LLC | 0.00% | New | 55 | $429 |
"% of holder's portfolio" is SMMT's weight in each manager's 13F, not the share of Summit Therapeutics-Spon ADR the manager owns.